A Study of LY4005130 in Healthy Participants

Exclusion Criteria

• •Are an individual of childbearing potential (IOCBP)
• •Have known allergies to LY4005130, related compounds, or any components of the formulation
• •Have received a live vaccine within 28 days of screening or intend to do so during the study or within 28 days after the study
• •* Non-live or inactivated vaccinations are allowed
• •* Bacillus Calmette Guerin vaccine must not have been administered within 12 months before screening
• •Had a surgical procedure within 12 weeks before screening;
• •* during the study, or
• •* within 28 days after the study
• •Have a history of allergy to medications that could be used to treat infusion reactions, or to the drug excipients
• •Have a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, significant history of atopy, or a history of severe posttreatment hypersensitivity reactions. These reactions include, but are not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis
• •Have a diagnosis or history of malignant disease within 5 years prior to screening, with the following exceptions
• •* Basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, or
• •* Cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to screening
• •Have had breast cancer within the past 10 years
• •Have a history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection that, in the opinion of the sponsor or investigator, poses an unacceptable risk to the participant
• •Have a current or recent acute, active infection